Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) provides US trial update
Published by Arron Aatkar, PhD

Newron Pharmaceuticals has provided an update following its Type A meeting with the US FDA. The meeting was related to the hold on the enrolment of new patients at US sites as part of the Phase III ENIGMA-TRS 2 trial, evaluating evenamide in treatment resistant schizophrenia. Newron reported that the discussion was constructive, and that the parties covered potential actions towards the resolution of issues that led to the hold. Newron, as agreed with the regulators, plans to propose changes to address remaining concerns. Management is working towards resolving these issues in the near future.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.